Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 29, 2001

View Archived Issues

Digene cleared to market test for STDs in Japan

Ester and Pharmacopeia collaborate on small-molecule neurological drug discovery

FDA accepts amendment to approvable letter for Xyrem from Orphan Medical

Potential new antipsychotic from Solvay combines D2 antagonism and 5-HT reuptake inhibition

Basic and clinical studies on aripiprazole discussed in Istanbul

Addition of oral morphine to standard therapy significantly improves symptoms in resistant OCD

Improvement in functional constipation demonstrated for NT-3 in controlled trial

Feasibility of different schedule of administration assessed for ET-743 in clinical trial

Vertex highlights Q3 2001 progress

Combinations of Janssen farnesyltransferase inhibitor with other chemotherapeutic agents

MGI Pharma updates Q3 developments

Preliminary analysis of phase II data for LY-355703 results in trial suspension

GenVec continues to make advances with gene-based drug candidates

EB-1089 exerts significant chemopreventive effect in animal model of hepatocarcinoma

Acapodene advances to next phase of clinical trials as prostate cancer preventive

AtheroGenics updates product developments during third quarter

LDL receptor upregulators emerge from joint Tularik/Sumitomo program

Dual M3 and 5-HT4 antagonists claimed in recent patent by Sanofi-Synthelabo

Sanofi-Synthelabo describes novel V1-selective agents and their use

Chemokine receptor modulators reportedly useful for HIV infection, etc.

PDE4-inhibitory heterocyclic carboxamides patented by Merck

Finnish labs identify alpha2 blockers for use in CNS disorders

Ningalin B analogues as MDR reversal agents reported by Scripps

Oral Ono-3403 effective in murine skin cancer model

BT-99-25, a nonantisense oligonucleotide, blocks cell cycle progression and induces apoptosis

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 29, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for April 28, 2026
Chinese biotechs gain leverage as partners in dealmaking
BioWorld
China’s biotech ecosystem has crossed an inflection point, and Chinese biotechs are gaining leverage in dealmaking, executives from multinational companies said...
Roche identifies new TREM2 agonists
BioWorld Science
F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. have prepared and tested new compounds acting as triggering receptor expressed on myeloid cells 2 (TREM2)...
Plasticity, properly parsed, provides psychiatric platform
BioWorld
If Benjamin Braddock, of The Graduate fame, were a young neuroscientist in the 21st century instead of a liberal arts graduate in 1967, the advice he received...